So at a high level in drug development, there are really three key questions that we need to answer. Likewise, the VelocImmune technology gives us an unprecedented speed in producing new drugs candidates.

Our VelociGene technologies give us an unprecedented ability to precisely manipulate the mouse genome and work very rapidly. We can use that engine again, and again, and again to produce new drugs. These include things like VelociGene, VelocImmune, and together this suite of technologies gives us an engine for drug discovery. We've invested in a set of core technologies we call the VelociSuite Technologies. We have a rich genomic database, and we apply that across our organization, looking for new for new insights and to advance our research programs. We have a capability of combining human gene sequence data with electronic medical records. Our genetics research is focused on looking at differences in our genes and connecting that to diseases. We're one of the unique places where we've put such a big emphasis on human genetics and deep biology. One of the things that distinguishes Regeneron is that we are a founder-led organization.īoth Len and George are scientists, and they've really set the tone of focusing on science from the very beginning.Īnd it spreads the through the organization in terms of our mission, our vision, our activities, our behaviors. It's really cool because we go from the really big thought, the really big idea, all the way to seeing the impact on a person. We do that all at our campuses in New York, New Jersey, Ireland, and the UK.

We're one of the few companies in the world that go all the way from foundational discovery, to research, from research to development, to manufacturing and commercialization. One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies. We've done this by following the science. At Regeneron, we've been committed to making a difference in patients' lives for over 30 years.

Linkedin logo jpg